


## China's Sanyou Bio launches comprehensive monkeypox product line

30 August 2024 | News

### Product line features 65 items across three main categories



Sanyou Biopharmaceuticals (Shanghai) has announced the launch of a comprehensive product line targeting monkeypox, which includes antigens, monoclonal antibodies, and overexpression cell lines.

This product line features 65 items across three main categories: 26 natural epitope antigens, 28 high-affinity, high-specificity monoclonal antibodies and 11 overexpression cell lines. These products target multiple key sites on the surface of monkeypox virus, including A29L, M1R, H3L, E8L, A35R, B6R, and critical sites such as A28L, A30L, B21R, L1R and I1L, which are vital for viral infection and assembly.

Developed using Sanyou Bio's proprietary "over-trillion innovative antibody discovery" platform, the monoclonal antibodies span multiple species, including fully human, nano, and mouse antibodies. These antibodies are essential for therapeutic drug development, with high-affinity nano antibodies being particularly valuable for structural analysis and bispecific research. Additionally, the entire range of antibodies, natural epitope antigens, and overexpression cell lines can be utilized in diagnostic reagents and scientific research.

Dr Lang Guojun, CEO of Sanyou Bio, emphasised the company's rapid response capabilities, citing significant contributions during the COVID-19 pandemic. During that time, Sanyou Bio played a key role in the drug discovery and preclinical development of two innovative COVID-19 antibody therapies, which were published in leading journals such as *Science* and *Cell Research*, with related therapeutics advancing to clinical trials. With this new monkeypox product line, Sanyou Bio aims to strengthen the development of vaccines, therapeutics, diagnostic tools and research initiatives, furthering its commitment to global public health.